PARP Inhibition in the Treatment of Pancreatic Cancer: Current and Future Perspectives on Personalized Therapy

Download All
Learn how experts around the world use PARP inhibitors to optimally manage patients with pancreatic cancer and BRCA1/2 or other alterations causing homologous repair deficiency with focused commentaries, a podcast series, an expert video roundtable, and downloadable slideset.
Dirk Arnold, MD, PhD

ClinicalThought Commentaries

With the approval of olaparib, how will your treatment of patients with pancreatic cancer change?

Dirk Arnold, MD, PhD Released: October 5, 2021
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue